SCHEMBL3277516

SCHEMBL3277516

CCN(CC)CCNc1cccc2c1C(=O)c1c(NCCN(CC)CC)cccc1C2=O

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 7/20 0.79
MAPT P10636 5/20 0.56
KMT2A Q03164 3/20 0.56
MAPK1 P28482 3/20 0.56
MEN1 O00255 2/20 0.56
ALDH1A1 P00352 2/20 0.56
POLB P06746 2/20 0.56
RAD52 P43351 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
EGFR P00533 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
LMNA P02545 1/20 0.56
HTT P42858 1/20 0.56
RECQL P46063 1/20 0.56
BLM P54132 1/20 0.56
GAA P10253 1/20 0.55
DNMT1 P26358 1/20 0.55
SMARCA2 P51531 1/20 0.55
NSD2 O96028 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5605466 0.95 TERT (0.72) TERTMAPTKMT2AMAPK1MEN1
SCHEMBL9364080 0.94 TERT (0.71) TERTMAPTKMT2AMAPK1MEN1
SCHEMBL31218598 0.94 TERT (0.71) TERTMAPTKMT2AMAPK1MEN1
SCHEMBL5605310 0.91 TERT (0.79) TERTMAPTKMT2AMAPK1MEN1
SCHEMBL6364970 0.91 TERT (0.67) TERTMAPTKMT2AMAPK1MEN1
SCHEMBL10046651 0.89 TERT (0.65) TERTMAPTKMT2AMAPK1MEN1
SCHEMBL11688579 0.87 TERT (0.73) TERTMAPTKMT2AMAPK1MEN1
Hydrochloric Acid SCHEMBL11691265 0.85 TERT (0.71) TERTMAPTKMT2AMAPK1MEN1
SCHEMBL3416154 0.84 TERT (0.62) TERTMAPTKMT2AMAPK1MEN1
SCHEMBL7152625 0.83 TERT (0.57) TERTMAPTKMT2AMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202292-B2 Colored polymeric resin composition with 1,8-diaminoanthraquinone derivative, article made therefrom, and method for making the same GENERAL ELECTRIC COMPANY (US) 2007-04-10 US claimed
US-7691418-B2 Composition for inhibiting or preventing the formation of a biofilm OYSTERSHELL NV (BE) 2010-04-06 US disclosed
US-20070258913-A1 Composition for Inhibiting or Preventing the Formation of a Biofilm OYSTERSHELL NV (BE) 2007-11-08 US disclosed
US-7202292-B2 Colored polymeric resin composition with 1,8-diaminoanthraquinone derivative, article made therefrom, and method for making the same GENERAL ELECTRIC COMPANY (US) 2007-04-10 US disclosed
US-7087282-B2 Limited play optical storage medium, method for making the same GENERAL ELECTRIC COMPANY (US) 2006-08-08 US disclosed
EP-1647011-A1 LIMITED PLAY OPTICAL STORAGE MEDIUM, METHOD FOR MAKING THE SAME GENERAL ELECTRIC COMPANY (US) 2006-04-19 EP disclosed
EP-1646682-A1 COLORED POLYMERIC RESIN COMPOSITION, ARTICLE MADE THEREFROM, AND METHOD FOR MAKING THE SAME GENERAL ELECTRIC COMPANY (US) 2006-04-19 EP disclosed
WO-2005010090-A1 COLORED POLYMERIC RESIN COMPOSITION, ARTICLE MADE THEREFROM, AND METHOD FOR MAKING THE SAME GENERAL ELECTRIC COMPANY (US) 2005-02-03 WO disclosed
WO-2005010872-A1 LIMITED PLAY OPTICAL STORAGE MEDIUM, METHOD FOR MAKING THE SAME GENERAL ELECTRIC COMPANY (US) 2005-02-03 WO disclosed
US-20050014878-A1 Colored polymeric resin composition, article made therefrom, and method for making the same SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2005-01-20 US disclosed
US-20050013232-A1 Limited play optical storage medium, method for making the same SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2005-01-20 US disclosed
EP-0450021-B1 ANTI-CANCER COMPOUNDS BRITISH TECH GROUP (GB) 1994-02-02 EP disclosed
US-5132327-A ANTI-CANCER COMPOUNDS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1992-07-21 US disclosed
WO-1991005824-A1 ANTI-CANCER COMPOUNDS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1991-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258913-A1 Composition for Inhibiting or Preventing the Formation of a Biofilm NQO2, NFKBIA, CROCC TERT 851/4885MAPT 4695/4885KMT2A 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.